Get started
GILEAD SCIENCES DL-,001GILEAD SCIENCES DL-,001GILEAD SCIENCES DL-,001

GILEAD SCIENCES DL-,001

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

GIS trade ideas

GILD short term Earnings PlayWe’ve seen this before on Gilead pre-pandemic; It traded sideways above this zone for a little over a year on descending YOY earnings since 2016. Following the gap down 19 AUG, we’re now seeing a bullish MACD divergence plus an ascending RSI on the daily to signal a break of the recent down trend. With more positive news surrounding their COVID-19 treatment drug, Remdesivir, would love to see a short term build up before ER to the 67-70 zone. ER date has not been announced but is estimated to be on 10/22.
NASDAQ:GILDLong
by BarnardR
Long Gild - Covid Drug ($MRNA $GSK $INO $SPY $PFE $JNJ $MRK)see full chart at www.tradingview.com Gild Entry $62 area Target 1 $67 Target 2 $71 stoploss $59 Why this play? Trump used Gild's drug as part of his treatment, if he pulls thru with a full recovery. they will probably start pumping the news about this company and it'll finally have enough momentum to move back to the upside. What is Gild? Gilead Sciences, Inc., is an American biopharmaceutical company headquartered in Foster City, California that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi. Notable price upgrades Sep-30-20 Resumed Jefferies Buy $78 Sep-15-20 Upgrade Maxim Group Hold → Buy $88
NASDAQ:GILDLong
by WallSt007
3
Gilead sciences - long term investmentDear traders and followers, It’s time again for one of our popular stock analytics. Today we take a closer look at Gilead Sciences The California-based pharmaceutical and biotechnology company offers a very attractive mix of Corona’s special economy, a bit of takeover fantasy and a moderate evaluation. The drug Remdesivir, which is approved for Corona treatment, is expected to generate sales of almost two billion dollars this year, which according to Bloomberg’s 2021 estimate should increase by another 20 percent. The 2021 KGV of eleven is among the ten lowest in the entire Nasdaq 100. No wonder there is speculation that AstraZeneca wants to take over Gilead, given that both groups are complementary in their focus areas. If this is not enough as a reason to buy, the share traded around 40 percent below the record high looks at the nice lower reversal, which can be seen in the chart picture along with the medium-term upward trend. Technical view: Market has formed a triangle formation since 2014 (after a strong up rally) and broke out of it at the beginning of March. The price is atm within correction movement which is expected to end at the drawn buy area at around 70 $. We´ve set our buy orders at this point. Feel free to leave a comment or to share your ideas in the comments section Please hit the like button if you share or like this idea. Thanks for your support !
NASDAQ:GILDLong
by DK_Investment
8